Glimepiride Accord (Glimepiride)

Glimepiride Accord is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and weight management alone do not achieve adequate glycemic control.

• As monotherapy in patients with newly diagnosed type 2 diabetes.
• In combination with metformin when metformin alone is insufficient.
• As adjunct to other oral antidiabetic agents such as thiazolidinediones.
• For patients who require additional glucose lowering after lifestyle measures.
• In combination with insulin for patients needing tighter control.
• For patients with renal impairment where dose adjustment is appropriate.

The safety profile of Glimepiride Accord includes both frequent, mild reactions and less common, potentially serious events.

Common

• Low blood sugar (hypoglycemia), especially if meals are missed.
• Weight gain.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Fatigue or weakness.
• Visual disturbances.
• Dry mouth.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as rash, itching, or swelling.
• Blood disorders like leukopenia or thrombocytopenia.
• Liver enzyme elevations.

When prescribing Glimepiride Accord, clinicians should consider several precautionary factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function before initiating therapy.
• Monitor blood glucose regularly to detect hypoglycemia.
• Use caution in elderly patients due to increased sensitivity.
• Adjust dose in patients with cardiovascular disease.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Review concomitant medications that may potentiate hypoglycemia.

Glimepiride Accord can interact with several drugs, affecting blood sugar levels or increasing adverse effects.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors such as fluconazole, which can raise glimepiride concentrations.
• MAO‑B inhibitors, which may enhance hypoglycemic risk.
• Alcohol, especially in excess, which can potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may affect glucose control.
• Anticoagulants like warfarin, as glimepiride may alter INR.
• Corticosteroids, which may increase blood glucose and require dose adjustment.
• Antidepressants such as SSRIs, which may have variable effects on glucose metabolism.